| *Sponsored
(NYSE American: MAIA) Battles $2.00 Psychological Chart Resistance + Breaking News Today June 5th Greetings, Friend!
With $2.00 psychological resistance being tested today, MAIA Biotechnology, Inc. (NYSE American: MAIA) may be on the verge of gaining some serious attention.
A pre-market breakthrough of that level while climbing to $2.19 showed that potential resistance may be waning for MAIA. Plus, after the bell, it has climbed from its open to test $2.00 resistance on its chart once again.
Plus, and this is important, MAIA is finding itself above 4 key technical chart levels which signals support could be growing significantly in key spots.
Furthermore, the company shared fresh news this morning!
Check it out: MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer
From the article:
"It is gratifying to see that our treatment further extends lives for these hard-to-treat patient populations, especially in third-line NSCLC treatment where patients are most resistant to therapy," said MAIA Chairman and CEO Vlad Vitoc, M.D. "This new benchmark of 17.8 months median OS is nearly triple the recognized SOC data for third-line NSCLC found in medical literature. We believe this is a substantial indicator of the potential ateganosine has to shift the NSCLC treatment landscape."
Review my initial (NYSE American: MAIA) report below and consider this biotech profile for your radar before it's too late. -----
There is a remarkable biotech company capturing attention within the medical community for its groundbreaking approach to cancer therapy.
By focusing on the underlying mechanisms that drive tumor growth, this company is addressing critical challenges that have long limited the effectiveness of existing treatments.
Recent clinical data demonstrate significant promise, and the team behind these advancements brings deep expertise and an unwavering commitment to patient outcomes.
As the conversation around next-generation oncology solutions intensifies, this company stands out as a leader to watch.
And here's the kicker. This isn't just any random profile. It's a past champ.
Brought to your a couple months back, it has since catapulted from an alert day's open of $1.95 to a high of $2.74 in May.
That's a move of approximately 40% short term!
After a recent pullback, time could now be ticking once again to consider this breakout idea for your watchlist: MAIA Biotechnology, Inc. (NYSE American: MAIA).
MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer.
Their lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. | 
